Diagnostics company Owlstone Medical has announced a strategic collaboration with Actelion Pharmaceuticals to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
Actelion will solely fund the development programme. The collaboration will initially involve collecting breath exhaled Volatile Organic Compounds (VOCs) from over 1,000 patients using Owlstone Medical’s proprietary sampling device, ReCIVA from sites in the UK, US and other countries in the EU. These VOCs will be analysed by Owlstone Medical to identify those that are associated with PH, in order to develop biomarker signature(s) that can help facilitate earlier detection of the disease.
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease where the blood pressure increases in the vessels that transport blood from the heart to the lungs, placing strain on the right side of the heart and often leading to heart failure.
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Owlstone Medical was founded with the objective of improving the early diagnosis of disease in order to save lives through the application of Breath Biopsy. This strategic collaboration with Actelion, which is focused on improving the lives of those suffering from PH and PAH, represents a tremendous opportunity to do just that. This is particularly true in underdiagnosed areas such as PH, where early diagnosis is difficult and so screening has to be simple, reliable, and cost effective. We believe Breath Biopsy will deliver a program from discovery through to the launch of a test to the market, and this novel approach will make a real difference for the healthcare of patients suffering from PH.”
